Results 91 to 100 of about 2,418 (169)

The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). [PDF]

J Neurochem, 2022
Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, Ramaekers JG.   +6 more
europepmc   +1 more source

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. [PDF]

Neuropsychopharmacology
Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D.   +23 more
europepmc   +1 more source

Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. [PDF]

ACS Med Chem Lett, 2022
Kargbo RB.
europepmc   +1 more source

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. [PDF]

Front Pharmacol, 2021
Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG.   +5 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial. [PDF]

Int J Neuropsychopharmacol
Mueller MJ, Aicher HD, Dornbierer DA, Marten L, Suay D, Meling D, Elsner C, Wicki IA, Müller J, Poetzsch SN, Caflisch L, Hempe A, Steinhart CP, Puchkov M, Kost J, Landolt HP, Seifritz E, Quednow BB, Scheidegger M.   +18 more
europepmc   +1 more source

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. [PDF]

Neuropsychopharmacology
Erne L, Vogt SB, Müller L, Nuraj A, Becker A, Klaiber A, Zuparic M, Varghese N, Eckert A, Rudin D, Luethi D, Liechti ME.   +11 more
europepmc   +1 more source

The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action. [PDF]

Addict Biol
Tap SC.
europepmc   +1 more source

Ayahuasca and Its Main Component <i>N,N</i>-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind. [PDF]

Biomedicines
Melani A, Papini G, Bonaso M, Biso L, Kolachalam S, Bragazzi NL, Conversano C, Orrù G, Longoni B, Scarselli M.   +9 more
europepmc   +1 more source

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. [PDF]

Cell Mol Life Sci
Egger K, Aicher HD, Cumming P, Scheidegger M.   +3 more
europepmc   +1 more source

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of <i>N,N</i>-dimethyltryptamine and harmine in a meditation retreat. [PDF]

Imaging Neurosci (Camb)
Egger K, Meling D, Polat F, Seifritz E, Avram M, Scheidegger M.   +5 more
europepmc   +1 more source